RO-282653

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameRO-282653
Drug Alias NameROCHE-282653RO-28-2653
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase inhibitors
TargetsMatrix metalloproteinase
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A